

Isabelle Barber is appointed to Exonhit Management Board

Paris, France – September 7, 2011 –Exonhit (Alternext : ALEHT) announces the appointment of Isabelle Barber, Executive Vice-President, Diagnostics Division, as a member of its Management Board. This decision taken by the Supervisory Board of July 28th 2011 was effective immediately.

Isabelle, with 17 years of international experience in healthcare and biotech, 11 of which in the diagnostics industry, joined Exonhit in September 2010 as Senior Vice-President, Global Marketing for the Diagnostics Division. Currently Executive Vice-President, Diagnostics Division, Isabelle is in charge of the entire diagnostics activity: from strategy to R&D and commercialization.

« We are very happy that Isabelle joins Exonhit Management Board: she brings to the management team her knowledge and expertise of the diagnostics industry as well as her strategic vision of molecular diagnostics, two key elements for the company growth and execution of its strategic plan » commented Laurent Condomine, President of the Supervisory Board. « Her appointment reflects the high quality of her performance and contribution and underlines the will of the Supervisory Board to increase strategic thinking at Exonhit and successfully transition the company to becoming a key player in personalized medicine.

Isabelle Barber, 43, started her career as a biomolecular chemist: first, as a R&D Senior Scientist at Isis Pharmaceuticals then as a Director of Chemistry at Genset. From July 1999 to August 2010, she worked on both side of the Atlantic for Ortho Clinical Diagnostics, a Johnson & Johnson company, where she held roles of increasing responsibilities in a variety of functions spanning from Customer Support and Training, Quality, Strategic Planning, Market Access and Development, to Global Marketing for the entire Clinical Laboratory portfolio of tests and reagents, a line of business representing more than one billion USD in annual sales.

Isabelle holds a Ph.D in Biomolecular Chemistry from the University of Montpellier, and an MBA from IAE (Business Administration Institute) in Strasbourg, France.

Exonhit Management Board is led by Loïc Maurel. Other members are Hervé Duchesne de Lamotte, CFO, and Matthew Pando, Executive Vice-President Therapeutics Division.

About Exonhit

Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer's disease. Exonhit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with Allergan.

Exonhit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris and is part of the NYSE Alternext OSEO innovation index. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contacts for Media & Investors

Hervé Duchesne de Lamotte, CFO

+33 1 53 94 52 49

herve.delamotte@exonhit.com